News

New Home at Alexandria LaunchLabs

New Home at Alexandria LaunchLabs

We have officially moved from our founding location at BioLabs@NYU Langone to Alexandria LaunchLabs, a leading life sciences innovation space in New York City. This move marks another step forward in our mission to develop next-generation oncolytic viruses for cancer therapy. Why This Move Matters Relocating our lab, to us, is more than a logistical undertaking—it reflects the evolution of our platform and the increasing scale of our research. Over the past few years, BioLabs@NYU Langone provided an environment that…

Reflections from AACR 2025: Advancing Oncolytic Viral Therapies (OVTs)

Reflections from AACR 2025: Advancing Oncolytic Viral Therapies (OVTs)

We recently had the opportunity to attend the 2025 American Association for Cancer Research (AACR) conference in Chicago. It is one of the largest and most prestigious gatherings in the world for cancer researchers, clinicians, and biotech companies. It was an invaluable experience—an opportunity not only to present our latest findings but also to connect with peers and explore the exciting evolution of oncolytic viral therapies (OVTs). Here’s a recap of the key trends we observed and how they align…

Showcasing data on our oncolytic viral therapy at AACR 2025

Showcasing data on our oncolytic viral therapy at AACR 2025

We showcase breakthrough data on our engineered oncolytic viral therapy, a first-in-class for pediatric liver cancer We are excited to share that Humane Genomics is returning to the American Association for Cancer Research (AACR) annual meeting for the third time! With over 23,000 attendees (in 2024), AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world. It is an honor to be invited back to this prestigious event where we will be showcasing our groundbreaking…

Announcing our Series Seed financing

Announcing our Series Seed financing

Six years ago, I had dinner with my friend and co-founder Andrew Hessel and he told me something that blew my mind: it is possible to 3D print DNA. With this technology, we could engineer viruses for all kinds of purposes. One of the most compelling is to use these viruses as cancer therapies. My curiosity went into overdrive. Soon, we were spending long hours with our other co-founder Chad Moles, Chief Science Officer, figuring out how to turn this…

Introduction – Manal

Introduction – Manal

Tell me a bit about yourself. Hi there! I’m Manal, a born and bred New Yorker. Being a true child of the diaspora, I also spent a chunk of my life in Lebanon, my parents’ homeland. I’m a self-professed nerd (and proud), so in retrospect, it doesn’t seem too surprising that I eventually became a scientist. My love of science began long before I ever stepped foot into a laboratory. Growing up, I was fascinated by the wonders of the…

Improving the success rate of engineering RNA viruses

Improving the success rate of engineering RNA viruses

In our previous post on this topic, we introduced the details on how to make a replicating RNA virus from its genome (DNA). In this post, we want to zoom in on the details a bit more and share how we have improved the success rate of engineering viruses to over 70%. If you have not read the previous post on the science of viral engineering and want to get a first level understanding on how the process works, go…

The Role of miRNA in Modern Medicine and the Nobel Prize Recognition

The Role of miRNA in Modern Medicine and the Nobel Prize Recognition

Today, the 2024 Nobel Prize in Medicine was awarded to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNAs (miRNAs). This discovery has transformed our understanding of how cells regulate genes and opened new possibilities for diagnosing and treating diseases. But what exactly are miRNAs, and why are they so significant? What Are miRNAs?  miRNAs are tiny pieces of RNA, typically about 22 nucleotides long, that act as master regulators in cells. They don’t code for proteins themselves…

The Science of Engineering Viruses

The Science of Engineering Viruses

Introduction Have you ever wondered how viruses are made in a lab setting? Although it may sound like complex wizardry, the process is quite approachable with a bit of molecular biology under your belt. This blog post will try to explain the process of engineering viruses, making it hopefully understandable to anyone curious about the steps involved. Understanding Virus Structure Fig.1. Simplified viral structure Before diving into virus creation, it is essential to understand what a virus consists of, in…

Reflections from AACR: The evolving landscape of Oncolytic Viral Therapies

Reflections from AACR: The evolving landscape of Oncolytic Viral Therapies

We recently attended the American Association for Cancer Research (AACR) conference. It’s the largest cancer research gathering in the U.S., and we were thrilled to present our latest results and learn from peers. Here’s a snapshot of the current developments in oncolytic viral therapies (OVTs). The State of Oncolytic Viral Therapies Diverse Targets and Approaches:Presentations at AACR showed a strong interest in OVTs, featuring 39 oncolytic viruses from 23 companies and 11 research groups. These therapies aim to combat a…

Join Us at AACR 2024: Celebrating Progress in Cancer Research

Join Us at AACR 2024: Celebrating Progress in Cancer Research

We’re thrilled to announce that we’re returning to the American Association for Cancer Research (AACR) annual meeting for the second time! It’s an honor to be invited back to this prestigious event where we’ll be showcasing our groundbreaking work in the field of cancer therapeutics. AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world, with over 20,000 attendees.  Our Progress Since Last Year Last year’s experience in Orlando was unforgettable. We connected with fellow…